Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy
- 2 February 2021
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (5), 482-483
- https://doi.org/10.1001/jama.2020.17308
Abstract
This JAMA Clinical Guidelines Synopsis summarizes the National Comprehensive Cancer Network’s 2019 guidelines on management of immunotherapy-related toxicities,This publication has 9 references indexed in Scilit:
- Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitisJournal for ImmunoTherapy of Cancer, 2019
- Faculty Opinions recommendation of Myocarditis in patients treated with immune checkpoint inhibitors.Published by H1 Connect ,2019
- Immune Checkpoint Inhibitor Toxicity in 2018Jama-Journal Of The American Medical Association, 2018
- High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanomaCancer, 2018
- Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD AndersonJournal for ImmunoTherapy of Cancer, 2018
- Myocarditis in Patients Treated With Immune Checkpoint InhibitorsJournal of the American College of Cardiology, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitisCancer Immunology, Immunotherapy, 2017
- Inflammatory Arthritis Due to Immune Checkpoint Inhibitors: Challenges in Diagnosis and TreatmentImmunotherapy, 2016